HK1128929A1 - 聚乙二醇化的突變的肉毒梭菌毒素 - Google Patents
聚乙二醇化的突變的肉毒梭菌毒素Info
- Publication number
- HK1128929A1 HK1128929A1 HK09108510.5A HK09108510A HK1128929A1 HK 1128929 A1 HK1128929 A1 HK 1128929A1 HK 09108510 A HK09108510 A HK 09108510A HK 1128929 A1 HK1128929 A1 HK 1128929A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- modified
- botulinum toxin
- chain
- tag
- exhibits
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06005300A EP1834962A1 (de) | 2006-03-15 | 2006-03-15 | PEGyliertes mutiertes Clostridium botulinum Toxin |
PCT/EP2007/002296 WO2007104567A2 (de) | 2006-03-15 | 2007-03-15 | Pegyliertes mutiertes clostridium botulinum toxin |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1128929A1 true HK1128929A1 (zh) | 2009-11-13 |
Family
ID=36603470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09108510.5A HK1128929A1 (zh) | 2006-03-15 | 2009-09-17 | 聚乙二醇化的突變的肉毒梭菌毒素 |
Country Status (17)
Country | Link |
---|---|
US (4) | US8003601B2 (zh) |
EP (2) | EP1834962A1 (zh) |
JP (1) | JP5232021B2 (zh) |
KR (1) | KR101454273B1 (zh) |
CN (1) | CN101432296B (zh) |
AT (1) | ATE443078T1 (zh) |
AU (1) | AU2007224669B2 (zh) |
BR (1) | BRPI0708907A2 (zh) |
CA (1) | CA2638862A1 (zh) |
DE (1) | DE502007001546D1 (zh) |
ES (1) | ES2334283T3 (zh) |
HK (1) | HK1128929A1 (zh) |
IL (1) | IL193777A (zh) |
MX (1) | MX2008011495A (zh) |
RU (1) | RU2426739C2 (zh) |
WO (1) | WO2007104567A2 (zh) |
ZA (1) | ZA200807284B (zh) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
EP1834962A1 (de) * | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
US8252897B2 (en) * | 2007-06-21 | 2012-08-28 | Angelica Therapeutics, Inc. | Modified toxins |
US8470314B2 (en) * | 2008-02-29 | 2013-06-25 | Angelica Therapeutics, Inc. | Modified toxins |
JP5799397B2 (ja) | 2008-06-12 | 2015-10-28 | イプセン・バイオイノベーション・リミテッドIpsen Bioinnovation Limited | 癌の抑制 |
EP3590956A1 (en) | 2008-06-12 | 2020-01-08 | Ipsen Bioinnovation Limited | Suppression of neuroendocrine diseases |
CA2733283A1 (en) | 2008-08-29 | 2010-03-04 | Merz Pharma Gmbh & Co. Kgaa | Clostridial neurotoxins with altered persistency |
GB0820970D0 (en) | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
US8993715B2 (en) * | 2009-07-06 | 2015-03-31 | Canon Kabushiki Kaisha | Labeled protein and method for obtaining the same |
WO2011023213A1 (en) * | 2009-08-28 | 2011-03-03 | Merz Pharma Gmbh & Co. Kgaa | Modified chemodenervating agents |
MX2012013381A (es) * | 2010-05-20 | 2013-02-21 | Allergan Inc | Toxinas de clostridium degradables. |
GB201108108D0 (en) | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
CA2902905A1 (en) | 2013-03-15 | 2014-09-25 | Claude Geoffrey Davis | Modified toxins |
GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
ES2642916T3 (es) | 2014-06-06 | 2017-11-20 | Galit KLEINER-FISMAN | Toxina botulínica para su uso en el tratamiento de la paratonia |
US11014970B2 (en) | 2014-11-07 | 2021-05-25 | Kineta Chronic Pain, Llc | Modifications and uses of conotoxin peptides |
ES2788999T3 (es) | 2014-12-23 | 2020-10-23 | Merz Pharma Gmbh & Co Kgaa | Envase prellenado de toxina botulínica |
EP3822286A1 (en) | 2015-01-09 | 2021-05-19 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
WO2017063743A1 (en) | 2015-10-14 | 2017-04-20 | Merz Pharma Gmbh & Co. Kgaa | Improvements to ultrasound-based therapy of photoaged tissue |
CA3021231A1 (en) | 2016-04-19 | 2017-10-26 | Griffon Pharmaceuticals Inc. | Pegylated bioactive peptides and uses thereof |
TWI737742B (zh) | 2016-06-22 | 2021-09-01 | 德商梅茲製藥有限兩合公司 | 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用 |
US11400136B2 (en) | 2017-06-19 | 2022-08-02 | President And Fellows Of Harvard College | Methods and compositions for treating a microbial infection |
JP7046173B2 (ja) * | 2017-10-11 | 2022-04-01 | エランコ・ユーエス・インコーポレイテッド | ブタg-csf変異体とその使用 |
MX2020007596A (es) | 2018-01-29 | 2020-09-03 | Ipsen Biopharm Ltd | Neurotoxinas botulinicas para escindir una proteina de receptor de union a factor sensible a n-etilmaleimida soluble (snare) no neuronal. |
EP3752128A1 (de) * | 2018-02-16 | 2020-12-23 | Bontana Therapies Gmbh | Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung |
JP2021525251A (ja) | 2018-05-21 | 2021-09-24 | イプセン バイオファーム リミテッドIpsen Biopharm Limited | 骨癌誘発性アロディニアの抑制 |
GB201815844D0 (en) | 2018-09-28 | 2018-11-14 | Ipsen Biopharm Ltd | Therapeutic & comestic uses of botulinum neurotoxin serotype e |
GB201815817D0 (en) | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
US20220016221A1 (en) | 2018-12-05 | 2022-01-20 | Ipsen Biopharm Limited | Treatment of symptoms of traumatic brain injury |
GB201900621D0 (en) | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
US20230120677A1 (en) * | 2020-01-21 | 2023-04-20 | Trustees Of Dartmouth College | Immunologically optimized botulinum toxin light chain variants |
GB202103372D0 (en) | 2021-03-11 | 2021-04-28 | Ipsen Biopharm Ltd | Modified clostridial neurotoxins |
GB202104294D0 (en) | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
WO2024069191A1 (en) | 2022-09-30 | 2024-04-04 | Ipsen Biopharm Limited | Clostridial neurotoxin for use in a treatment of bladder pain syndrome |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19925739A1 (de) | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
US6903187B1 (en) | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
AU2002320127A1 (en) * | 2001-06-21 | 2003-01-08 | Surromed, Inc. | Covalent coupling of botulinum toxin with polyethylene glycol |
EP1784420B1 (en) * | 2004-09-01 | 2008-12-03 | Allergan, Inc. | Degradable clostridial toxins |
EP1834962A1 (de) * | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
-
2006
- 2006-03-15 EP EP06005300A patent/EP1834962A1/de not_active Withdrawn
-
2007
- 2007-03-15 BR BRPI0708907-4A patent/BRPI0708907A2/pt not_active IP Right Cessation
- 2007-03-15 EP EP07723281A patent/EP1994048B1/de active Active
- 2007-03-15 ES ES07723281T patent/ES2334283T3/es active Active
- 2007-03-15 US US12/282,601 patent/US8003601B2/en not_active Expired - Fee Related
- 2007-03-15 RU RU2008140368/10A patent/RU2426739C2/ru not_active IP Right Cessation
- 2007-03-15 DE DE502007001546T patent/DE502007001546D1/de active Active
- 2007-03-15 CN CN200780015607.5A patent/CN101432296B/zh not_active Expired - Fee Related
- 2007-03-15 MX MX2008011495A patent/MX2008011495A/es active IP Right Grant
- 2007-03-15 AT AT07723281T patent/ATE443078T1/de active
- 2007-03-15 AU AU2007224669A patent/AU2007224669B2/en not_active Ceased
- 2007-03-15 CA CA002638862A patent/CA2638862A1/en not_active Abandoned
- 2007-03-15 KR KR1020087023540A patent/KR101454273B1/ko not_active IP Right Cessation
- 2007-03-15 JP JP2008558725A patent/JP5232021B2/ja not_active Expired - Fee Related
- 2007-03-15 WO PCT/EP2007/002296 patent/WO2007104567A2/de active Application Filing
-
2008
- 2008-08-22 ZA ZA200807284A patent/ZA200807284B/xx unknown
- 2008-08-31 IL IL193777A patent/IL193777A/en not_active IP Right Cessation
-
2009
- 2009-09-17 HK HK09108510.5A patent/HK1128929A1/zh not_active IP Right Cessation
-
2011
- 2011-07-19 US US13/185,925 patent/US8298550B2/en not_active Expired - Fee Related
-
2012
- 2012-09-21 US US13/624,493 patent/US8912140B2/en not_active Expired - Fee Related
-
2014
- 2014-11-11 US US14/538,132 patent/US9186396B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP5232021B2 (ja) | 2013-07-10 |
ES2334283T3 (es) | 2010-03-08 |
US8298550B2 (en) | 2012-10-30 |
CN101432296A (zh) | 2009-05-13 |
KR101454273B1 (ko) | 2014-10-28 |
CN101432296B (zh) | 2014-07-02 |
BRPI0708907A2 (pt) | 2011-06-21 |
DE502007001546D1 (de) | 2009-10-29 |
US20130156747A1 (en) | 2013-06-20 |
IL193777A (en) | 2011-09-27 |
IL193777A0 (en) | 2011-08-01 |
EP1834962A1 (de) | 2007-09-19 |
US20150166977A1 (en) | 2015-06-18 |
ATE443078T1 (de) | 2009-10-15 |
US20090118193A1 (en) | 2009-05-07 |
US20110294747A1 (en) | 2011-12-01 |
KR20080106451A (ko) | 2008-12-05 |
JP2009531026A (ja) | 2009-09-03 |
RU2426739C2 (ru) | 2011-08-20 |
AU2007224669B2 (en) | 2010-05-13 |
WO2007104567A2 (de) | 2007-09-20 |
US8003601B2 (en) | 2011-08-23 |
WO2007104567A3 (de) | 2007-11-01 |
CA2638862A1 (en) | 2007-09-20 |
AU2007224669A1 (en) | 2007-09-20 |
ZA200807284B (en) | 2009-04-29 |
US9186396B2 (en) | 2015-11-17 |
MX2008011495A (es) | 2008-09-24 |
EP1994048A2 (de) | 2008-11-26 |
RU2008140368A (ru) | 2010-04-20 |
EP1994048B1 (de) | 2009-09-16 |
US8912140B2 (en) | 2014-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200807284B (en) | Pegylated mutated clostridium botulinum toxin | |
UA103215C2 (uk) | Поліпептид з ксиланазною активністю | |
CY1116285T1 (el) | Ανασυνδυασμενες ν-γλυκοζυλιωμενες πρωτεϊνες απο προκαρυωτικα κυτταρα | |
WO2007018619A3 (en) | Chimeric therapeutic agents | |
UA103216C2 (uk) | Поліпептид з ксиланазною активністю | |
EA200702408A1 (ru) | Аналоги глюкагонподобного пептида-2 (glp-2) | |
UA102506C2 (ru) | Селективные аналоги глюкагоноподобного пептида-2 (glp-2) | |
WO2007035600A3 (en) | Natriuretic activities | |
UA94244C2 (ru) | Анти-cgrp антагонистическое антитело и фармацевтическая композиция, которая его включает | |
WO2011068953A3 (en) | Atoxic recombinant holotoxins of clostridium difficile as immunogens | |
WO2009025117A1 (ja) | Cdca1ペプチド及びこれを含む薬剤 | |
NZ607069A (en) | Modified relaxin polypeptides and their uses | |
PE20160507A1 (es) | Diferenciacion de celulas madre mesenquimales | |
ATE536367T1 (de) | Bindende peptidomimetika und deren verwendungen | |
NZ602702A (en) | Modified fgf-21 polypeptides and their uses | |
WO1999003881A3 (fr) | Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique | |
DE602005025141D1 (de) | In Zellen eindringende Peptide als Träger für Moleküle | |
ATE548380T1 (de) | Mutante des hgf-precursor-proteins und aktivierte form davon | |
EP1982992A4 (en) | HLA BINDING PEPTIDE, PRE-STEP, DNA DOMAGING AND RECOMBINANT VECTOR | |
DE602004028266D1 (de) | Angiogene peptide und ihre verwendungen | |
WO2006122205A3 (en) | Conus californicus neurotoxins | |
EP1915617A4 (en) | METHOD AND COMPOSITIONS FOR IDENTIFYING A PEPTIDE WITH INTERMOLECULAR INTERACTION WITH AN INTERESTING OBJECTIVE | |
SG170757A1 (en) | Polypeptide having esterase activity and recombinant esterase and use thereof | |
AR029130A1 (es) | Gen enzimatico y sus productos de expresion | |
WO2008140703A3 (en) | Synthetic peptide materials for joint reconstruction, repair and cushioning |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20180315 |